Evidence map›Paper›PMID 41185725›Full record

ArticleIJU case reports2025

Effect of Hemodialysis on Total and Free Lenvatinib Concentrations in a Patient With Metastatic Renal Cell Carcinoma.

Takahiro Ito, Shimpei Yamashita, Manabu Suno, Ayaka Iwata, Yasuo Kohjimoto, Kazuo Matsubara

Abstract read
In one paragraph

Article in IJU case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Takahiro ItoSchool of Pharmaceutical Sciences Wakayama Medical University Wakayama Japan.
Shimpei YamashitaDepartment of Urology Wakayama Medical University Wakayama Japan.ORCID https://orcid.org/0000-0001-7402-6164
Manabu SunoSchool of Pharmaceutical Sciences Wakayama Medical University Wakayama Japan.ORCID https://orcid.org/0000-0002-1511-7725
Ayaka IwataSchool of Pharmaceutical Sciences Wakayama Medical University Wakayama Japan.
Yasuo KohjimotoDepartment of Urology Wakayama Medical University Wakayama Japan.
Kazuo MatsubaraSchool of Pharmaceutical Sciences Wakayama Medical University Wakayama Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Lenvatinib (LEN) concentrations in patients undergoing hemodialysis (HD) have not been examined. Herein, we report the effect of HD on total and free LEN concentrations in a patient with mRCC. Case Presentation: The hemodialyzed patient was a 55-year-old Japanese male who was treated with 20 mg LEN daily. The area under the plasma concentration-time curve for LEN from 0 to 24 h (AUC Conclusion: Although the free LEN concentration is reduced just after HD, LEN will have sufficient pharmacological activity on HD days for patients undergoing HD.

Indexed as

free drug concentrationhemodialysislenvatinibmetastatic renal cell carcinomatherapeutic drug monitoring

Identifiers

PMID41185725
PMCPMC12579997

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.